New €300 Million State-Of-The-Art Drug Manufacturing Site In Freiburg, Germany

Highly potent drugs hold promise for treating cancer, cardiovascular diseases, and other illnesses in patients around the world. Employing flexible, fast, and resource-efficient production methods is critical for shortening the development and production times of highly potent drugs so patients can receive treatment faster.

Pfizer CentreOne’s new high containment (HighCon), state-of-the-art drug manufacturing site has now been completed following a €300 million investment to help offer greater support to European partners across a range of formulation manufacturing services. This investment into the existing Freiburg site has now transformed it into a center for the efficient, reliable production and packaging of innovative medicines for the global market.

The machines and processes at the Freiburg facility are intelligently networked with the help of information and communication technologies. This added flexibility and efficiency will better support drug sponsors throughout the entirety of the development lifecycle.